Closing the loop: optimizing physicians' operational and strategic behavior.

P T Sergeant; E H Blackstone

doi:10.1016/s0003-4975(99)00627-x

Home/Archive/PubMed

PubMed · 10475398

Closing the loop: optimizing physicians' operational and strategic behavior.

P T Sergeant·E H Blackstone

View original source ↗Export metadata ↓

Abstract

Clinical databases are essential elements in optimizing medical care. They are no finality by themselves, but essential elements in the generation of knowledge. Optimal medical care starts with optimal care based on existing knowledge. This care continues with the registration of the variability in morbidity, comorbidity, and therapy, but also the registration of the early and late outcome. This should then allow the generation of structured inferences based on this registration and the closure of the loop, by treating patients according to this newly created evidence.

Explore related subjects

Belgium Cause of Death Coronary Artery Bypass Databases, Factual Follow-Up Studies Hospital Mortality Humans Managed Care Programs Quality Assurance, Health Care Registries Survival Analysis Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

P T Sergeant, E H Blackstone. 1999. Closing the loop: optimizing physicians' operational and strategic behavior.. https://doi.org/10.1016/s0003-4975(99)00627-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

The future of precision oncology and artificial intelligence in Belgium: scenarios and policy responses.

PURPOSE: Precision medicine, also known as personalized medicine, enables the provision of tailored health services to patients. In the prevention, early detection, and treatment of cancers, precision medicine is highly promising, given the increasing use of genomic profiling for diagnosis and adapting therapies in several tumor types. Artificial Intelligence (AI) can support this process by analyzing vast amounts of relevant data. However, high-quality data and financial investments in the health system are essential for the implementation of precision medicine and AI solutions in routine cancer care. DESIGN/METHODOLOGY/APPROACH: Building on the quantitative outcomes of a foresight exercise published in another study, this article collects qualitative data to gain more detailed insights into the future of precision oncology in Belgium and discusses the role of AI in this field. It reports the results of a series of expert workshops, focusing on four hypothetical future scenarios that are centered around technological and economic issues that must be overcome for the widespread use of precision oncology in Belgium. FINDINGS: The study concludes that all four scenarios discussed in the workshops would require supportive policy measures in Belgium, which should go beyond mere technological and economic considerations, such as involving patient associations and the public in policy design or creating multi-disciplinary expert groups for precision medicine. ORIGINALITY/VALUE: To the best of our knowledge, this is the first study to employ foresight methodology to illustrate possible future scenarios, scrutinize feasible approaches for implementing precision oncology in Belgium, and discuss the use of AI in this context.

Belgium↗

PubMed2000

Belgium considers legalising euthanasia.

Explore the source record for details and available documents.

Belgium↗

PubMed2000

Novel mutations of the RPGR gene in RP3 families.

X-linked retinitis pigmentosa is a severe retinal degeneration characterized by night blindness and visual field constriction, leading to complete blindness within the third decade of life. Mutations in the RPGR gene (retinitis pigmentosa GTPase regulator), located on Xp21.1 in the RP3 region, have been associated with an RP phenotype. Further to our previous mutation screening of RPGR in families segregating with the RP3 locus, we have expanded this study to include other 8 RP3 pedigrees. Here we report the results of this expanded study and the identification of five mutations in RPGR, four of which are novel (IVS6+5 G>A, 950-951delAA, 963 T>C, EX8del) and one of which occurs in the donor splice site of intron 1 (IVS1+1 G>A). These findings bring the proportion of "RP3 genotypes" with a mutation in this gene to 27% (10/37). Hum Mutat 15:386, 2000.

Belgium↗